MedTrace Logo

Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC

NCT03130764 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-12-06

No results posted yet for this study

Summary

Despite aggressive surgery and chemotherapy, the risk of lung cancer recurrence remains high in most patients. This study aims to determine if a novel immune therapy consisting of two drugs is feasible and potentially increases the chance of cure in lung cancer patients after surgery and standard chemotherapy. The immune-based therapy being given in this study consists of two medications named durvalumab and tremelimumab.

Conditions

Interventions

DRUG

Durvalumab

1500 mg, IV over 1 hour Every 4 weeks for 1 year

DRUG

Tremelimumab

75 mg, IV over 1 hour Every 4 weeks for 4 doses

Sponsors & Collaborators

Principal Investigators

  • Adrian Sacher, M.D. · Columbia University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-31
Primary Completion
2017-11-30
Completion
2017-11-30
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03130764 on ClinicalTrials.gov